Spatial-Temporal Change in Quantitative Total Bone Imaging and Circulating Tumor Cells in Metastatic Castration-Resistant Prostate Cancer Treated With Enzalutamide

Cancer is a dynamic disease which, over time, may result in nonuniform distribution of distinct tumor cell subpopulations at different sites (spatial heterogeneity) or an increase in molecularly diverse cells (temporal heterogeneity). Here we report the exploratory objectives of tumor burden and CTC analysis using QTBI and VERSA in men with mCRPC to bone treated with enzalutamide.

Interlesional Response Assessment With 18F-Sodium Fluoride (18F-NaF) PET/CT in Men With Chemotherapy-Naive Bone Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide

18F-NaF positron emission tomography/computed tomography (PET/CT) scan is an approved tool to detect and evaluate osteoblastic metastases that is more sensitive and specific than conventional bone scintigraphy. Here we assess the proportion of men treated with enzalutamide with responding lesions by 18F-NaF PET/CT scan at the time of prostate-specific antigen (PSA), standard radiographic, or clinical progression.

Spatiotemporal evolution of lesion response heterogeneity to 177Lu-DOTATATE therapy in advanced gastroenteropancreatic neuroendocrine tumors

The purpose of this investigation was to understand and quantify the inter-lesion heterogeneity in treatment response seen on 68Ga-DOTATATE PET/CT imaging over the course of Lutathera therapy

Per the US FDA, AIQ technology is indicated for use in the identification, quantification, and evaluation of Regions of Interest (ROIs) from digital medical images, including PET and CT. Any other applications of AIQ technology are for research purposes only.